Advertisement

Journal of Endocrinological Investigation

, Volume 29, Issue 11, pp RC35–RC38 | Cite as

Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers

  • G. M. Leggio
  • T. Incognito
  • G. Privitera
  • M. R. Marano
  • F. Drago
Rapid Communication

Abstract

Objective. To evaluate the relative bioavailability of T4 sodium and liothyronine sodium (T3), administered in single doses as oral solution (drops) and tablet forms, according to two separate study protocols. Methods. Twenty-four healthy, male volunteers were included in both studies. Two test drugs containing T4 or T3 (T4-lbsa and T3-lbsa, respectively) were compared to two reference drugs, ie Eutirox 100 and Ti-tre tablets, respectively. A single oral dose of 100 μg (1 ml or 1 tablet) of T4 and 20μg (1 ml or 1 tablet) of T3 were administered with an open, randomized, crossover design. T4 and T3 serum concentrations were determined by a validated immunoassay inelectro-chemo-luminescence method. Results. Study 1: after administration of T4-lbsa oral solution, Cmax was 14.26± 0.61 μg/dl, AUC0−t was 282.70 ±14.29 μg/dl/h, Tmax was 2.71 ± 0.25 h. After administration of Eutirox 100 tablets, Cmax was 14.34± 0.59 μg/dl, AUC0−t was 279.42± 9.59 μg/dl/h and Tmax was 2.65± 0.23 h. The 90% confidence interval ratios between test/reference drugs were 1.01 for AUC0−t and 0.99 for Cmax. Study 2: after administration of T3-lbsa oral solution, Cmax was 3.19± 0.25 ng/ml, AUC0−t was 44.79± 2.15 ng/ml/h and Tmax was 2.31 ± 0.25 h. After administration of Ti-tre tablets, Cmax was 3.16± 0.23 ng/ml, AUC0−twas 45.19± 2.19 ng/ml/h and Tmax was 2.44± 0.34 h. The 90% confidence interval ratios between test /reference drugs were 0.99 for AUC0−tand 1.01 for Cmax. Conclusions. The bioavailability of the two oral solutions (T4-lbsa and T3-lbsa oral solutions) and the corresponding tablet forms (Eutirox 100 and Ti-tre tablets) were confirmed and they can be considered bioequivalent and therapeutically interchangeable.

Key-words

Bioavailability levothyroxine liothyronine lioequivalence formula 

References

  1. 1.
    Nygaard B. Primary hypothyroidism. Clin Evid 2003, 10: 715–20 Update in: Clin Evid 2004, 12: 898–903.PubMedGoogle Scholar
  2. 2.
    Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 1995, 96: 2828–38.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Escobar-Morreale HF, del Rey FE, Obregon MJ, de Escobar GM. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology. 1996, 137: 2490–502.PubMedGoogle Scholar
  4. 4.
    Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999, 340: 424–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Wiersinga WM. Thyroid hormone replacement therapy. Horm Res 2001, 56 (Suppl. 1): 74–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Westlake WJ. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci 1972: 61: 1340–1.PubMedCrossRefGoogle Scholar
  7. 7.
    Meier CA, Maisey MN, Lowry A, Muller J, Smith MA. Interindividual differences in the pituitary-thyroid axis influence the interpretation of thyroid function test. Clin Endocrinol (Oxf) 1993, 39: 101–7.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2006

Authors and Affiliations

  • G. M. Leggio
    • 1
  • T. Incognito
    • 2
  • G. Privitera
    • 2
  • M. R. Marano
  • F. Drago
    • 1
  1. 1.Department of Experimental and Clinical PharmacologyUniversity of CataniaCataniaItaly
  2. 2.Pharmacokinetic Unit, Unifarm Research CenterUniversity of CataniaCataniaItaly

Personalised recommendations